

ChromaDex to Participate in “Conquering Aging” Briefing with Frost & Sullivan

Frank Jaksch, ChromaDex Co-Founder & Executive Chairman, to discuss nutraceuticals, aging, and NAD

IRVINE, Calif., Sept. 11, 2018 — ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN[®] and consumer product TRU NIAGEN[®], today announced its participation in Growth Innovation Leadership (GIL) briefing titled, “Conquering Aging: Novel Technology Disruptions in the Anti-aging Industry.”

The live webinar, hosted by Frost & Sullivan, will take place on Tuesday, September 18, 2018, from 11:00 AM to 12:00 PM Eastern Time. The webinar will offer expert insight from thought leaders and industry experts to share ideas in the anti-aging space.

Frank Jaksch, ChromaDex Co-Founder & Executive Chairman, will discuss nutraceuticals in the anti-aging space, the critical role of NAD (nicotinamide adenine dinucleotide), as well as the cutting-edge science behind TRU NIAGEN.

The informative webinar will cover key insights:

- Discover innovations in anti-aging drugs and therapies, novel nutrition, and digital tools;
- Engage with thought leaders to understand the dynamics around significant market trends, innovative business models, and game-changing companies; and
- Uncover key investment opportunities and growth potential.

For more information and to register for the webinar, please visit <http://frost.ly/2pr>. The event will also be recorded and available for on-demand viewing at <http://frost.ly/1ti>.

About TRU NIAGEN[®]:

TRU NIAGEN[®] is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN[®] nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN[®]. Multiple clinical trials demonstrate NIAGEN[®] is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN[®] has twice been successfully reviewed under FDA’s new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).

About ChromaDex:

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the

way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, **NIAGEN**[®] nicotinamide riboside, sold directly to consumers as **TRU NIAGEN**[®], is backed with clinical and scientific research, as well as extensive IP protection. **TRU NIAGEN**[®] is helping the world AGE BETTER[®]. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.

ChromaDex Media Contact:

Alex Worsham, Director of Strategic Partnerships
949-648-3775
alexw@chromadex.com

ChromaDex Investor Relations Contact:

Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com

